Separately, ValuEngine downgraded shares of Vermillion from a hold rating to a sell rating in a research report on Friday, July 28th.
Shares of Vermillion (NASDAQ:VRML) traded up $0.07 on Thursday, hitting $1.74. 34,319 shares of the stock traded hands, compared to its average volume of 104,852. The company has a quick ratio of 3.16, a current ratio of 3.21 and a debt-to-equity ratio of 0.34.
Vermillion (NASDAQ:VRML) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). The company had revenue of $0.90 million for the quarter. Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%.
Institutional investors have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC increased its position in shares of Vermillion by 145.8% in the third quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock worth $390,000 after acquiring an additional 128,494 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Vermillion by 0.7% in the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock worth $1,068,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Birchview Capital LP increased its position in shares of Vermillion by 7.9% in the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock worth $4,433,000 after acquiring an additional 180,000 shares in the last quarter. 35.55% of the stock is currently owned by institutional investors and hedge funds.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
What are top analysts saying about Vermillion Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vermillion Inc. and related companies.